Goal and Hypothesis: During cancer progression, the cells encounter many stress signals. If beyond repair, the cells have built-in mechanisms to eliminate themselves. The successful cancer cells managed to foil this hardwired stress response. In fact, it appears that cancer cells can co-opt some tumor suppressors to become oncogenes. TGF? is the best-known example exhibiting this """"""""Jekyll and Hyde"""""""" conversion. ATF3, a stress- inducible gene, is a regulatory gene that was recently identified to have a dichotomous role in cancer progression: it is pro-apoptotic in non-transformed breast epithelial cells, but protects the malignant cells from stress and promotes their metastasis. The long-term objective is to understand the cancer dichotomy using ATF3 as a handle to address this issue. This proposal will focus on the oncogenic aspect of ATF3 in breast cancer.
Aim 1 will test the hypothesis that the interaction of ATF3 with Smad3, a protein in the TGF? pathway, plays an important role in the oncogenic activity of ATF3 in advanced breast cancer cells. This will be tested by structure-function analyses, including domain swap and site-directed mutagenesis.
Aim 2 will test the hypothesis that ATF3 exerts its oncogenic action in malignant cells, at least in part, by regulating downstream target genes. Potential target promoters will be tested by chromatin immunoprecipitation assay and transcription assay to determine whether they are the direct target genes of ATF3. In addition, the biological significance of their regulation by ATF3 will be tested.
Aim 3 will test the hypothesis that ATF3 is important for macrophage-cancer interaction. Both gain- and loss- of-function approaches, using in vitro co-culture and in vivo fat pad injection models, will be taken to test whether ATF3 plays a role in the ability of cancer cells to interact with macrophages. Significance: ATF3 is a new regulator that has a dichotomous role in cancer progression, and may play a role in stroma-cancer interaction. Because it is induced by anti-cancer drugs, its oncogenic function indicates that these drugs may have undesired effects. Information from the proposal may provide clues for rational designs of anti-cancer treatment, thus potentially changing the clinical practice in the future.

Public Health Relevance

Despite the tremendous advances in early detections and treatments, breast cancer becomes incurable once metastasized beyond the regional lymph nodes. Thus, to combat breast cancer, it is essential to better understand its metastasis. This proposal investigates a master switch gene that regulates breast cancer metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA118306-03
Application #
7849469
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Ault, Grace S
Project Start
2008-07-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
3
Fiscal Year
2010
Total Cost
$255,000
Indirect Cost
Name
Ohio State University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Wolford, Chris C; McConoughey, Stephen J; Jalgaonkar, Swati P et al. (2013) Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Invest 123:2893-906
Hoetzenecker, Wolfram; Echtenacher, Bernd; Guenova, Emmanuella et al. (2012) ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med 18:128-34
Darlyuk-Saadon, Ilona; Weidenfeld-Baranboim, Keren; Yokoyama, Kazunari K et al. (2012) The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter. Biochim Biophys Acta 1819:1142-53
Wang, Hongbo; Jiang, Ming; Cui, Hongmei et al. (2012) The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol 32:3190-202
Hai, Tsonwin; Jalgaonkar, Swati; Wolford, Christopher C et al. (2011) Immunohistochemical detection of activating transcription factor 3, a hub of the cellular adaptive-response network. Methods Enzymol 490:175-94
Hasin, Tal; Elhanani, Ofer; Abassi, Zaid et al. (2011) Angiotensin II signaling up-regulates the immediate early transcription factor ATF3 in the left but not the right atrium. Basic Res Cardiol 106:175-87
Hai, Tsonwin; Wolford, Christopher C; Chang, Yi-Seok (2010) ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expr 15:1-11
Kim, Hyun Keol; Flexman, Molly; Yamashiro, Darrell J et al. (2010) PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer. Biomed Opt Express 1:812-824
Akram, Ali; Han, Bing; Masoom, Hussain et al. (2010) Activating transcription factor 3 confers protection against ventilator-induced lung injury. Am J Respir Crit Care Med 182:489-500
Zmuda, Erik J; Qi, Ling; Zhu, Michael X et al. (2010) The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic beta-cell dysfunction. Mol Endocrinol 24:1423-33

Showing the most recent 10 out of 14 publications